sirt 3

SIRT-IN-3, a potent inhibitor of SIRT1 with an IC50 value of 17 μM, exhibits approximate 4-fold and 14-fold greater selectivity for SIRT1 over SIRT2 and SIRT3, with respective IC50 values of 74 μM for SIRT2 and 235 μM for SIRT3 [1].

Nicotinamide riboside increases NAD[+] levels and activates SIRT1 and SIRT3, culminating in enhanced oxidative metabolism and protection against high fat diet-induced metabolic abnormalities.

Nicotinamide riboside chloride, also known as NR and SRT647, is a pyridine-nucleoside form of vitamin B3 that functions as a precursor to nicotinamide adenine dinucleotide or NAD+.

3-TYP (3-(1H-1,2,3-triazol-4-yl) pyridine) is a selective SIRT3 inhibitor.

SIRT-IN-1 is a potent inhibitor of SIRT1, SIRT2, and SIRT3, with IC50 values of 15, 10, and 33 μM, respectively

SIRT-IN-2 is a potent SIRT1 2 3 inhibitor [IC50s of 4, 1, and 7 μM, respectively].

SJ-106C, a SIRT inhibitor, exhibits IC50 values of 0.59, 0.12, and 0.49 μM against SIRT1 2 3, respectively. This compound specifically targets mitochondria and inhibits the growth of DLBCL tumors.

SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1 2 3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.

Decapeptide-12, a competitive inhibitor of mushroom tyrosinase with an IC50 of 40 µM and a Kd of 61.1 μM for the C-terminal residue of tyrosinase, is a small oligopeptide that reduces melanin content in melanocytes by interacting with tyrosinase and increasing transcription of SIRT. It is utilized in researching melanogenesis, senescence, and inflammation [1] [2] [3].